BACKGROUND: Genetically engineered mouse models play important roles in analyses of prostate development and pathobiology. While constitutive genetic gain- and loss-of-function models have contributed significantly to our understanding of molecular events driving these processes, the availability of a tightly regulated inducible expression system could extend the utility of transgenic approaches. Here, we describe the development of a Tet-regulatory system that employs Hoxb13 transcriptional control elements to direct reverse tetracycline transactivator (rtTA) expression in the prostate. METHODS: Using recombineering technology, the rtTA gene was placed under Hoxb13 cis-regulatory transcriptional control in the context of a 218-kb bacterial artificial chromosome. F(1) offspring carrying the Hoxb13-rtTA transgene were bred to a Tetracycline operator-Histone 2B-Green Fluorescent Protein (TetO-H2BGFP) responder line. Detailed reporter gene expression analyses, including doxycycline (Dox) induction and withdrawal kinetics, were performed in Hoxb13-rtTA|TetO-H2BGFP double transgenic adult mice and embryos. RESULTS: Dox-dependent GFP expression was observed exclusively in the prostate and distal colon epithelia of double transgenic mice. Reporter gene mRNA was detected in the prostate within 6 hr of Dox exposure, and was extinguished within 24 hr after Dox withdrawal. Furthermore, Dox-induced reporter gene expression persisted after castration. CONCLUSIONS: The Hoxb13-rtTA transgenic system provides a powerful tool for conditional Tet operator-driven transgene expression in the normal prostate and during disease progression. Used in conjunction with other prostate pathology models, these mice will enable precise, temporally controlled analyses of gene function and can provide opportunities for detailed analyses of molecular events underlying prostate diseases.
BACKGROUND: Genetically engineered mouse models play important roles in analyses of prostate development and pathobiology. While constitutive genetic gain- and loss-of-function models have contributed significantly to our understanding of molecular events driving these processes, the availability of a tightly regulated inducible expression system could extend the utility of transgenic approaches. Here, we describe the development of a Tet-regulatory system that employs Hoxb13 transcriptional control elements to direct reverse tetracycline transactivator (rtTA) expression in the prostate. METHODS: Using recombineering technology, the rtTA gene was placed under Hoxb13 cis-regulatory transcriptional control in the context of a 218-kb bacterial artificial chromosome. F(1) offspring carrying the Hoxb13-rtTA transgene were bred to a Tetracycline operator-Histone 2B-Green Fluorescent Protein (TetO-H2BGFP) responder line. Detailed reporter gene expression analyses, including doxycycline (Dox) induction and withdrawal kinetics, were performed in Hoxb13-rtTA|TetO-H2BGFP double transgenic adult mice and embryos. RESULTS:Dox-dependent GFP expression was observed exclusively in the prostate and distal colon epithelia of double transgenic mice. Reporter gene mRNA was detected in the prostate within 6 hr of Dox exposure, and was extinguished within 24 hr after Dox withdrawal. Furthermore, Dox-induced reporter gene expression persisted after castration. CONCLUSIONS: The Hoxb13-rtTAtransgenic system provides a powerful tool for conditional Tet operator-driven transgene expression in the normal prostate and during disease progression. Used in conjunction with other prostate pathology models, these mice will enable precise, temporally controlled analyses of gene function and can provide opportunities for detailed analyses of molecular events underlying prostate diseases.
Authors: Peter S Nelson; Nigel Clegg; Hugh Arnold; Camari Ferguson; Michael Bonham; James White; Leroy Hood; Biaoyang Lin Journal: Proc Natl Acad Sci U S A Date: 2002-08-16 Impact factor: 11.205
Authors: Scott B Shappell; George V Thomas; Richard L Roberts; Ron Herbert; Michael M Ittmann; Mark A Rubin; Peter A Humphrey; John P Sundberg; Nora Rozengurt; Roberto Barrios; Jerrold M Ward; Robert D Cardiff Journal: Cancer Res Date: 2004-03-15 Impact factor: 12.701
Authors: Søren Warming; Nina Costantino; Donald L Court; Nancy A Jenkins; Neal G Copeland Journal: Nucleic Acids Res Date: 2005-02-24 Impact factor: 16.971
Authors: Ling Hao; Yatao Shi; Samuel Thomas; Chad M Vezina; Sagar Bajpai; Arya Ashok; Charles J Bieberich; William A Ricke; Lingjun Li Journal: Int J Mass Spectrom Date: 2018-09-22 Impact factor: 1.986
Authors: Ling Hao; Samuel Thomas; Tyler Greer; Chad M Vezina; Sagar Bajpai; Arya Ashok; Angelo M De Marzo; Charles J Bieberich; Lingjun Li; William A Ricke Journal: Am J Physiol Renal Physiol Date: 2019-04-17
Authors: Zoila A Lopez-Bujanda; Michael C Haffner; Matthew G Chaimowitz; Nivedita Chowdhury; Nicholas J Venturini; Radhika A Patel; Aleksandar Obradovic; Corey S Hansen; Joanna Jacków; Janielle P Maynard; Karen S Sfanos; Cory Abate-Shen; Charles J Bieberich; Paula J Hurley; Mark J Selby; Alan J Korman; Angela M Christiano; Angelo M De Marzo; Charles G Drake Journal: Nat Cancer Date: 2021-07-19
Authors: Zoila A Lopez-Bujanda; Aleksandar Obradovic; Thomas R Nirschl; Laura Crowley; Rodney Macedo; Alexandros Papachristodoulou; Timothy O'Donnell; Uri Laserson; Jelani C Zarif; Ran Reshef; Tiezheng Yuan; Mithil K Soni; Emmanuel S Antonarakis; Michael C Haffner; H Benjamin Larman; Michael M Shen; Pawel Muranski; Charles G Drake Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751